MMAF intermediate 1

• Description:

  MMAF intermediate 1 is an intermediate in the synthesis of MMAF (HY-15579) . MMAF (Monomethylauristatin F) is a potent inhibitor of tubulin polymerization and the cytotoxic (ADC Cytotoxin) component of classic antibody drug conjugates (ADCs), such as Vorsetuzumab mafodotin and SGN-CD19A[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  ADC Payload

• Type:

  Reference compound

• Related Pathways:

  Antibody-drug Conjugate/ADC Related

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/mmaf-intermediate-1.html

• Purity:

  99.20

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N1[C@@H](CCC1)[C@@H]([C@@H](C)C(N[C@H](C(OC)=O)CC2=CC=CC=C2)=O)OC)OC(C)(C)C

• Molecular Formula:

  C24H36N2O6

• Molecular Weight:

  448.55

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Lee JW, et al. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 1;16 (9) :2562-70. [Content Brief]

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C (Powder, protect from light, stored under nitrogen)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [161485-82-1]